SPOCK1 overexpression confers a poor prognosis in urothelial carcinoma

Journal of Cancer

Volumn 7, Issue 4, 2016, Pages 467-476

  Ma, Li Jung ^a   Wu, Wen Jen ^b,c,d,e,f   Wang, Yu Hui ^g   Wu, Ting Feng ^h   Liang, Peir In ^d   Chang, I Wei ⁱ   He, Hong Lin ⁱ   Li, Chien Feng ^a,d,f,h,j  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^h SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

ⁱ I SHOU UNIVERSITY   (Taiwan)

^j NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

more..

Author keywords

Prognosis; SPOCK1; Transcriptome; Urothelial carcinoma

Indexed keywords

TRANSCRIPTOME;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CELL MOTILITY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; METASTASIS FREE SURVIVAL; MITOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPOCK1 GENE; STATISTICAL ANALYSIS; SURVIVAL ANALYSIS; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; URINARY TRACT CARCINOMA; UROTHELIUM;

EID: 84971572052     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.13625     Document Type: Article

References (29)

1. Liao AC, Li CF, Shen KH, et al. Loss of lactate dehydrogenase B subunit expression is correlated with tumour progression and independently predicts inferior disease-specific survival in urinary bladder urothelial carcinoma. Pathology 2011; 43(7): 707-712.
2. Liang PI, Li WM, Wang YH, et al. HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer 2012; 12: 611. doi: 10.1186/1471-2407-12-611.
3. Cheng L, Zhang S, MacLennan GT, et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2011; 42(4): 455-481. doi: 10.1016/j.humpath.2010.07.007.
4. Cheng L, Lopez-Beltran A, MacLennan GT, et al. Neoplasms of the urinary bladder. In: Urologic surgical pathology, 2nd ed. Philadelphia: Elsevier/Mosby; 2008: 259-352.
5. Fujita K, Uemura M, Yamamoto Y, et al. Preoperative risk stratification for cancer-specific survival of patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy. Int J Clin Oncol 2015; 20(1): 156-163. doi: 10.1007/s10147-014-0695-1.
6. [Internet] UpToDate: Joaquim Bellmunt. Treatment of metastatic urothelial cancer of the bladder and urinary tract. This topic last updated: June 26, 2015. http://www.uptodate.com/contents/treatment-of-metastatic-urothelial-cancer-of-the-bladder-and-urinary-tract?source=search_result&search=treatment+of+metastatic+urothelial&selectedTitle=1%7E150
7. Bradshaw AD. Diverse biological functions of the SPARC family of proteins. Int J Biochem Cell Biol 2012; 44(3): 480-488. doi: 10.1016/j.biocel.2011.12.021.
8. Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Update 2008; 11(6): 231-246. doi: 10.1016/j.drup.2008.08.005.
9. Colin C, Baeza N, Bartoli C, et al. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using suppression subtractive hybridization. Oncogene 2006; 25(19): 2818-2826.
10. Li Y, Chen L, Chan TH, et al. SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice. Gastroenterology 2013; 144(1): 179-191. e4. doi: 10.1053/j.gastro.2012.09.042.
11. Liang PI, Wang YH, Wu TF, et al. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. J Clin Pathol 2013; 66(7): 573-582. doi: 10.1136/jclinpath-2012-201278.
12. Budwit-Novotny DA, McCarty KS, Cox EB, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986; 46(10): 5419-5425.
13. McClelland RA, Finlay P, Walker KJ, et al. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 1990; 50(12): 3545-3550.
14. Mayanagi T, Sobue K. Diversification of caldesmon-linked actin cytoskeleton in cell motility. Cell Adh Migr 2011; 5(2): 150-159.
15. Alliel PM, Perin JP, Jollès P, et al. Testican, a multidomain testicular proteoglycan resembling modulators of cell social behaviour. Eur J Biochem 1993; 214(1): 347-350.
16. Edgell CJ, BaSalamah MA, Marr HS. Testican-1: a differentially expressed proteoglycan with protease inhibiting activities. Int Rev Cytol 2004; 236: 101-122.
17. Dhamija R, Graham JM Jr, Smaoui N, et al. Novel de novo SPOCK1 mutation in a proband with developmental delay, microcephaly and agenesis of corpus callosum. Eur J Med Genet 2014; 57(4): 181-184. doi: 10.1016/j.ejmg.2014.02.009.
18. Liu YZ, Guo YF, Wang L, et al. Genome-wide association analyses identify SPOCK as a key novel gene underlying age at menarche. PLoS Genet 2009; 5(3): e1000420. doi: 10.1371/journal.pgen.1000420.
19. Leja J, Essaghir A, Essand M, et al. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol 2009; 22(2): 261-272. doi: 10.1038/modpathol.2008.174.
20. Miao L, Wang Y, Xia H, et al. SPOCK1 is a novel transforming growth factor-ß target gene that regulates lung cancer cell epithelial-mesenchymal transition. Biochem Biophys Res Commun 2013; 440(4):792-797. doi: 10.1016/j.bbrc.2013.10.024.
21. Shu YJ, Weng H, Ye YY, et al. SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway. Mol Cancer 2015; 14: 12. doi: 10.1186/s12943-014-0276-y.
22. Shan ZZ, Yan XB, Yan LL, et al. Overexpression of Tbx3 is correlated with epithelial-mesenchymal transition phenotype and predicts poor prognosis of colorectal cancer. Am J Cancer Res 2014; 5(1): 344-353.
23. Chen X, Guan X, Zhang H, et al. DAL-1 attenuates epithelial to mesenchymal transition in lung cancer. J Exp Clin Cancer Res 2015; 34: 3. doi: 10.1186/s13046-014-0117-2.
24. Ribeiro AS and Paredes J. P-Cadherin linking breast cancer stem cells and invasion: a promising marker to identify an "intermediates/metastable" EMT state. Front Oncol 2015; 4: 371. doi: 10.3389/fonc.2014.00371.
25. Adam L, Zhong M, Choi W, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15(16):5060-5072.
26. Wlazlinski A, Engers R, Hoffmann MJ, et al. Downregulation of several fibulin genes in prostate cancer. Prostate 2007; 67(16): 1770-1780.
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
28. Qian CN, Furge KA, Knol J, et al. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res 2009; 69(21): 8256-8264. doi: 10.1158/0008-5472.CAN-09-1689.
29. Cheng L, Zhang S, MacLennan GT, et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2011; 42(4):455-481. doi: 10.1016/j.humpath.2010.07.007.